Intensity Therapeutics reported encouraging early results for INT230-6 alongside standard treatment: 5 of 7 patients had no detectable cancer in the breast and affected lymph nodes. Only 7 patients are reported so far, but the findings give the company early support.
The results give Intensity Therapeutics early evidence that INT230-6 may help when used with existing treatment. The patient responses support promise for the drug, but results from a small first group cannot show how well it works for more patients.
Follow Intensity Therapeutics, Inc. (INTS) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for INTS